UNSPSC 51183707: Rivoglitazone hydrochloride

This classification denotes an anti-diabetic agent C20H19N3O4S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 60HQU68H8A, chemically known as 2,4-thiazolidinedione, 5-((4-((6-methoxy-1-methyl-1h-benzimidazol-2-yl)methoxy)phenyl)methyl)-, hydrochloride, but more generally known as rivoglitazone hydrochloride, which bears US NIH Compound Identifier 9889104. Most nations, for tariff and trade purposes, schedule rivoglitazone hydrochloride under HS 29341000 and SITC 51579.

As of Q4 2014, RIVOGLITAZONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN1C2CC(CCC2NC1COC3CCC(CC3)CC4C(=O)NC(=O)S4)OC.CL.

UNSPSC 51183707 Rivoglitazone hydrochloride is a Commodity code covering pharmaceutical active pharmaceutical ingredients and finished-dose medications procured through state and local cooperative purchasing agreements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary recent buying activity under this code, soliciting generic multi-source pharmaceuticals and over-the-counter products for distribution across participating state and local government facilities in Minnesota and Oregon. State purchasing offices and regional cooperative purchasing vehicles are the primary issuing bodies under this code, using RFPs to establish ongoing supply arrangements with manufacturers and distributors rather than one-time acquisitions. Vendors must meet regulatory compliance requirements including current Good Manufacturing Practices certification, Drug Supply Chain Security Act compliance, FDA approval, and comprehensive insurance coverage (commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000). Awarded vendors work through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and must maintain contractual relationships with at least two of the three, with chargeback systems in place, and demonstrate flexibility in pricing structures including flat price, net price formats (NF30, NF60, NF90), or WAC-minus arrangements.

MMCAP's RFP S1070000015802, posted January 20, 2026 with a response deadline of March 26, 2026, represents current activity under this code. The cooperative purchasing model spans Minnesota and Oregon with potential expansion to other MMCAP member states. Evaluation emphasizes price competitiveness (75 percent weight), with secondary criteria addressing fixed pricing for the contract term (10 percent), price competitiveness (75 percent), compliance with administrative fee data format requirements (5 percent), electronic data interchange capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Contract term runs two years for new vendors with optional MMCAP extensions, while incumbent vendor amendments align with existing expiration dates through June 30, 2028. Performance penalties ranging from $200 to $1,500 per violation apply for late reporting, missed onboarding timelines, or improper class-of-trade denials. All products must be available in the marketplace by May 15, 2026, with resulting agreements effective July 1, 2026. Vendors submit proposals through the ePro procurement system with pricing and product information in designated Excel spreadsheet format converted to CSV.